Table 1.
Demographic and baseline characteristics
| Category | HMS5552
|
Placebo (n=12) | Total (N=60) | |||||
|---|---|---|---|---|---|---|---|---|
| 5 mg (n=8) | 10 mg (n=8) | 15 mg (n=8) | 25 mg (n=8) | 35 mg (n=8) | 50 mg (n=8) | |||
| Age, years | ||||||||
| Mean (SD) | 22.9 (3.0) | 23.3 (2.4) | 24.3 (2.0) | 26.6 (3.6) | 22.0 (2.4) | 24.0 (2.4) | 25.8 (3.5) | 24.2 (3.1) |
| Sex, n (%) | ||||||||
| Male | 4 (50) | 4 (50) | 4 (50) | 4 (50) | 4 (50) | 5 (62.5) | 6 (50) | 31 (51.7) |
| Female | 4 (50) | 4 (50) | 4 (50) | 4 (50) | 4 (50) | 3 (37.5) | 6 (50) | 29 (48.3) |
| BMI, kg/m2 | ||||||||
| Mean (SD) | 21.0 (1.9) | 22.7 (1.3) | 21.1 (1.1) | 22.5 (0.8) | 22.0 (1.0) | 21.8 (1.7) | 20.7 (1.4) | 21.6 (1.5) |
| FPG, mmol/L | ||||||||
| Mean (SD)a | 4.8 (0.4) | 5.2 (0.2) | 4.9 (0.3) | 4.9 (0.4) | 4.8 (0.2) | 5.0 (0.2) | 4.9 (0.3) | 4.9 (0.3) |
| OGTT, mmol/L | ||||||||
| Mean (SD)b | 5.5 (1.2) | 6.0 (0.9) | 5.4 (0.6) | 5.2 (0.7) | 5.4 (1.2) | 5.9 (1.2) | 6.1 (0.8) | 5.7 (1.0) |
| HbA1c, % | ||||||||
| Mean (SD) | 5.3 (0.2) | 5.3 (0.3) | 5.0 (0.2) | 5.1 (0.5) | 5.2 (0.3) | 5.2 (0.2) | 5.0 (0.4) | 5.2 (0.3) |
Notes: N, number of subjects;
a
mean glucose level at baseline = (C−0.5 + C−0.25+ C0)/3; C−0.5, glucose score at 0.5 h pre-dose; C−0.25, glucose score at 0.25 h pre-dose; C0, glucose score before dosing on day 1.
b
Mean glucose level was detected 2 hours after supplement with 75 g glucose dissolved in 300 mL water at screening.
Abbreviations: BMI, body mass index; SD, standard deviation; FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; h, hour(s); HbA1c, glycated hemoglobin.